Lv310
270 积分 2026-01-19 加入
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial
1天前
待确认
The Lasting Impact of IL-2: Approaching 50 Years of Advancing Immune Tolerance, Cancer Immunotherapies, and Autoimmune Diseases
2天前
已完结
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
5天前
已完结
Commonalities Between pDCs and B Cells
7天前
已关闭
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
15天前
已完结
Positive results for obinutuzumab in SLE phase III trial
16天前
已完结
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions
19天前
已完结
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial
19天前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
19天前
已完结
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
19天前
已完结
皖公网安备34019202002308
